Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA and Marzano AV. Pustular psoriasis: from pathophysiology to treatment. Biomedicines 2021;9(12):1746.

Xu JM, Wang HM, Jin HZ. An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations. Expert Rev Clin Immunol. 2023;19:499–516.

CAS  PubMed  Google Scholar 

Spencer RK, Jin JQ, Elhage KG, Davis MS, Hakimi M, Bhutani T, Liao W. Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis of randomized clinical trials. J Am Acad Dermatol. 2023;89:423–5.

PubMed  Google Scholar 

Huang IH, Wu PC, Chiu HY, Huang YH. Small-molecule inhibitors and biologics for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis. Am J Clin Dermatol. 2024;25:347–58.

PubMed  Google Scholar 

Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17: e13688.

CAS  PubMed  Google Scholar 

Mohr J, Rahbar KN, Schön MP, Mössner R. Response of palmoplantar pustulosis to upadacitinib. J Dtsch Dermatol Ges. 2023;21:280–2.

PubMed  Google Scholar 

Rahbar KN, Tsianakas A, Assaf K, Mohr J, Wilsmann-Theis D, Mössner R. Response of palmoplantar pustulosis to upadacitinib: a case series of five patients. J Dtsch Dermatol Ges. 2023;21:1387–92.

Google Scholar 

Du N, Yang J, Zhang Y, Lv X, Cao L, Min W. Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients. Front Med (Lausanne). 2024;11:1476793.

PubMed  Google Scholar 

Huang D, Zhong X, Jiang Y, Kong L, Ma R, Lu J, Li Y, Shi Y. Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China. Br J Dermatol. 2024;191:616–23.

PubMed  Google Scholar 

Jiang Y, Liu X, Yao L, Huang D, Zhong X, Wang Y, Li Y, Lu J, Yu Q, Shi Y. Disagreement between physicians' and patients' assessment of disease activity in psoriasis: the speech registry study. J Eur Acad Dermatol Venereol 2024.39(6):e470–2

Jiang Y, Liu X, Ma R, Huang D, Wang Y, Zhong X, Yao L, Xu S, Li Y, Zhang X, Lu J, Shi Y. The impact of family history on clinical presentation and biologic treatment response in patients with psoriasis: a multicenter prospective cohort study. Am J Clin Dermatol 2025.26(2):291–300.

Committee On Psoriasis CSOD. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023; 56: 573–625.

Google Scholar 

Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Involvement of molecular mechanisms between t/b cells and il-23: from palmoplantar pustulosis to autoimmune diseases. Int J Mol Sci 2022; ;23(15):8261.

Heidemeyer K, May LM, Cazzaniga S, Yawalkar N, Naldi L. Palmoplantar pustulosis: a systematic review of risk factors and therapies. Psoriasis (Auckl). 2023;13:33–58.

CAS  PubMed  Google Scholar 

van Straalen KR, Kirma J, Yee CM, Bugada LF, Rizvi SM, Wen F, Wasikowski R, Fox J, Do TH, Schuler CT, Xing E, Macleod AS, Harms PW, Berthier CC, Kahlenberg JM, Leung M, Tsoi LC, Gudjonsson JE. Disease heterogeneity and molecular classification of inflammatory palmoplantar diseases. J Allergy Clin Immunol. 2024;154:1204–15.

PubMed  Google Scholar 

Mrowietz U, Burden AD, Pinter A, Reich K, Schäkel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase iia, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb). 2021;11:571–85.

PubMed  Google Scholar 

Leong HF, Wang WH, Peng F. Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review. Postepy Dermatol Alergol. 2024;41:262–9.

PubMed  PubMed Central  Google Scholar 

Kim DY, Kim JY, Kim TG, Kwon JE, Sohn H, Park J, Lim BJ, Oh SH. A comparison of inflammatory mediator expression between palmoplantar pustulosis and pompholyx. J Eur Acad Dermatol Venereol. 2013;27:1559–65.

CAS  PubMed  Google Scholar 

Mccluskey D, Benzian-Olsson N, Mahil SK, Hassi NK, Wohnhaas CT, Burden AD, Griffiths C, Ingram JR, Levell NJ, Parslew R, Pink AE, Reynolds NJ, Warren RB, Visvanathan S, Baum P, Barker JN, Smith CH, Capon F. Single-cell analysis implicates t(h)17-to-t(h)2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;150:882–93.

CAS  PubMed  Google Scholar 

Zheng YX, Chen XB, Wang ZY, Cai SQ, Zheng M, Koh LF, Common JE, Man XY. Efficacy of dupilumab in palmoplantar pustulosis treatment highlights the role of th2 inflammation. Allergy. 2024;79:1361–4.

CAS  PubMed  Google Scholar 

Wolk K, Wilsmann-Theis D, Witte K, Brembach TC, Kromer C, Gerdes S, Ghoreschi K, Reich K, Mössner R, Sabat R. Interleukin-19 levels are increased in palmoplantar pustulosis and reduced following apremilast treatment. Int J Mol Sci 2023; 24(2):1276

Bao L, Alexander JB, Shi VY, Mohan GC, Chan LS. Interleukin-4 up-regulation of epidermal interleukin-19 expression in keratinocytes involves the binding of signal transducer and activator of transcription 6 (stat6) to the imperfect stat6 sites. Immunology. 2014;143:601–8.

CAS  PubMed  PubMed Central  Google Scholar 

Gleeson D, Barker J, Capon F, Pink AE, Woolf RT, Smith CH, Mahil SK. Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic. Br J Dermatol. 2023;188:471–3.

PubMed  Google Scholar